HC Wainwright Forecasts CorMedix’s Q3 Earnings (NASDAQ:CRMD)

CorMedix Inc (NASDAQ:CRMD) – Research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of CorMedix in a note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.08). The consensus estimate for CorMedix’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.54 EPS.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. The firm had revenue of $101.93 million for the quarter, compared to the consensus estimate of $96.04 million. CorMedix had a return on equity of 40.52% and a net margin of 40.49%.

A number of other equities research analysts have also recently commented on CRMD. Leerink Partners lifted their target price on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Zacks Research upgraded CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Royal Bank Of Canada lifted their price objective on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of CorMedix in a research note on Monday, April 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a research note on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CorMedix presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Stock Performance

Shares of CorMedix stock opened at $7.67 on Tuesday. The business’s fifty day simple moving average is $8.12 and its 200 day simple moving average is $7.64. The firm has a market capitalization of $597.80 million, a P/E ratio of 3.58 and a beta of 1.50. CorMedix has a 12 month low of $6.13 and a 12 month high of $14.96. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.

Institutional Trading of CorMedix

A number of hedge funds have recently bought and sold shares of CRMD. BlackRock Inc. purchased a new position in shares of CorMedix during the second quarter worth approximately $49,644,000. Vanguard Group Inc. boosted its stake in shares of CorMedix by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 4,499,010 shares of the company’s stock valued at $52,323,000 after purchasing an additional 521,352 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of CorMedix by 34.6% during the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock valued at $40,397,000 after purchasing an additional 893,518 shares during the last quarter. Deerfield Management Company L.P. bought a new stake in CorMedix in the third quarter worth $38,656,000. Finally, State Street Corp boosted its position in CorMedix by 4.6% during the fourth quarter. State Street Corp now owns 1,920,861 shares of the company’s stock valued at $22,340,000 after buying an additional 85,240 shares during the period. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.